Physician profile
Mark E Ohlenkamp
NPI 1689048068
$6,026.24
in general payments reported to CMS, 2019-2025
24 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,287 · 2022: $2,222 · 2023: $1,310 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,619.16 | 2021-2025 | |
| Janssen Biotech, INC. | $563.17 | 2021-2023 | Remicade, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.22 | 2021-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $462.99 | 2021-2023 | Entyvio, Gattex |
| Gilead Sciences, INC. | $369.85 | 2021-2023 | |
| Celgene Corporation | $271.35 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $188.55 | 2021-2023 | Linzess |
| Pfizer INC. | $128.13 | 2021-2023 | |
| Redhill Biopharma INC. | $121.64 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Daiichi Sankyo INC. | $104.01 | 2022 | |
| Qol Medical, LLC | $93.41 | 2022-2023 | Sucraid |
| Janssen Scientific Affairs, LLC | $84.12 | 2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $74.39 | 2021-2023 | Ocaliva |
| Vivus LLC | $69.22 | 2021-2023 | Qsymia |
| Regeneron Healthcare Solutions, INC. | $45.52 | 2023 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $42.21 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $39.68 | 2021 | |
| Genzyme Corporation | $35.89 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $35.19 | 2022-2023 | |
| Mylan Institutional INC. | $35.05 | 2023 | Hulio |
| Aimmune Therapeutics, INC. | $34.04 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2023 | Cyltezo |
| Amgen INC. | $17.63 | 2021 | |
| Merck Sharp & Dohme LLC | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ohlenkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.